Recombinant IGF-I analog for cell culture — 200× more potent, 2× more stable than insulin.
LONG® R³ IGF-I is a recombinant analog of human insulin-like growth factor-I engineered to enhance cell-culture productivity. An arginine-for-glutamic-acid substitution at position three plus a 13-amino-acid N-terminal extension reduce affinity for IGF binding proteins over 1000-fold, greatly improving bioavailability over native IGF-I. It is 200 times more potent and twice as stable as insulin.
Unlike insulin, LONG® R³ IGF-I specifically activates the type-I IGF receptor, driving stronger proliferation and apoptosis-inhibition signalling for higher cell density, viability and extended culture duration. It delivers up to 62% improved volumetric productivity in CHO culture versus unsupplemented systems and 40% over insulin, with compatibility across many mammalian cell types.
Video: Watch on YouTube
- Biopharma
- Pharmaceutical